Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carissa Shepherd

Nurse Practitioner Greentown, IN Nurse Practitioner

NPI 1083756829 CMS profile 10493522

118 S Meridian St, Greentown, IN 46936

Open in the dashboard

General payments

$3,590

287 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carissa Shepherd of Greentown, IN is reported in the CMS Open Payments database as having received $3,590 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,054 71
2024 General $1,201 91
2023 General $832 77
2022 General $489 47
2021 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carissa Shepherd
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Carissa Shepherd were reported at $1,054. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Carissa Shepherd Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $15 $135 $40–$426 $132
2022 $489 $152 $48–$470 $149
2023 $832 $166 $54–$529 $160
2024 $1,201 $173 $55–$556 $164
2025 $1,054 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $979 120 payments
  2. AbbVie, Inc. $763 60 payments
  3. Lilly USA, LLC $486 35 payments
  4. AstraZeneca Pharmaceuticals LP $371 17 payments
  5. Dexcom, Inc. $153 8 payments
  6. Exact Sciences Corporation $122 7 payments
  7. Amgen Inc. $114 7 payments
  8. Pfizer Inc. $85 5 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $65 3 payments
  10. Corcept Therapeutics $61 3 payments
  11. Other $391 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,590 287 payments
Products named General payments · program years 2021–2025
  1. Ozempic $434 56 payments
  2. MOUNJARO $391 27 payments
  3. Wegovy $362 44 payments
  4. RYBELSUS $329 49 payments
  5. QULIPTA $312 23 payments
  6. UBRELVY $310 23 payments
  7. VRAYLAR $256 24 payments
  8. AIRSUPRA $236 9 payments
  9. ZEPBOUND $219 17 payments
  10. Dexcom G6 Transmitter $153 8 payments
  11. Other $1,610 101 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 86 drugs

Part D claims

3,807

Median for Nurse Practitioner: 389

Drug cost

$317,047

Median for Nurse Practitioner: $21,885

Branded share of claims

20.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 57 $101,255
Jardiance Empagliflozin Brand 33 $44,611
Mounjaro Tirzepatide Brand 30 $41,656
Eliquis Apixaban Brand 33 $40,236
Tresiba Flextouch U-100 Insulin Degludec Brand 25 $17,365
Linzess Linaclotide Brand 17 $12,819
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 28 $6,302
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 15 $4,719
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 17 $3,897
Albuterol Sulfate Hfa Albuterol Sulfate Brand 73 $2,934

The 10 drugs with the highest cost, of 86 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$52,913

Of which drugs: $11,108

Medicare patients

234

Average age 74

Services billed

1,120

142 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 28%
Ischemic heart disease 25%
Depression 24%
Chronic kidney disease 17%
COPD 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 21 21 $5,796
Vaccine for influenza for injection into muscle 90662 Office 50 50 $4,091

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $112
$112 — —
MOUNJARO
  • Lilly USA, LLC $96
$96 30 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $91
$91 — —
Wegovy
  • Novo Nordisk Inc $86
$86 — —
ZEPBOUND
  • Lilly USA, LLC $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record